Abbott’s Amplatzer Piccolo Occluder Device Repairs Infant with an Opening in the Heart at St. Joseph’s Children’s Hospital in West Central Florida, 1st in the Region

December 4, 2020

Abbott’s Amplatzer Piccolo Occluder Device is available at St. Joseph’s Hospital in West Central Florida.

The hospital notes infant Samantha Castellanos-Santana was delivered at 30 weeks gestation and was born with an opening in her heart, a condition known as patent ductus arteriosus. On Nov. 25, 2020, Samantha became the first patient in West Central Florida to have this type of heart defect repaired using Abbott’s Amplatzer Piccolo Occluder, a device smaller than a pea. St. Joseph’s Children’s Hospital is the region’s first hospital to use the Piccolo device, the only device U.S. FDA approved to close PDAs in premature babies.

“The Piccolo Occluder greatly increases our ability to close PDAs in the tiniest, most medically fragile babies, offering better options for patients who need corrective treatment and are high risk to undergo heart surgery,” said Dr. Jeremy Ringewald, a pediatric interventional cardiologist and the medical director of the Cardiac Catheterization Laboratory at St. Joseph’s Children’s Hospital in Tampa.

The most common congenital heart defect occurring in premature babies, PDA occurs when a blood vessel in the fetal heart that is supposed to close after birth – the ductus arteriosus – remains open. According to Dr. Ringewald, this opening is present in normally developing infants and typically closes spontaneously shortly after birth. Often in babies born prematurely, the PDA fails to close. This makes it difficult for babies to breathe normally due to increased blood flow to the lungs.

During Samantha’s procedure, Dr. Ringewald inserted a tiny catheter tube into a vein in the leg and guided the catheter into the PDA. He then advanced the self-expanding, wire mesh device through the catheter to spring open in the PDA, sealing it closed immediately.

“Since the device is implanted through a minimally invasive procedure, many of the premature babies who are critically ill in the neonatal intensive care unit can be weaned from the breathing machine soon after the procedure,” said Dr. Ringewald.

He adds that since patients do not outgrow the device after implantation, there is no need for additional procedures related to the PDA. Once the device is placed to seal the opening, it becomes part of the baby’s tissue, and is sealed for life.

St. Joseph’s Children’s Hospital is home to the Tampa Bay area’s only comprehensive congenital heart disease program, and its pediatric heart physicians perform hundreds of cardiac procedures each year to treat congenital and acquired heart conditions in children of any age, including newborns. A partnership between St. Joseph’s Children’s Hospital and the Children’s Hospital of Pittsburgh of UPMC provides families across Florida with unprecedented access to the highest level of pediatric heart care available. Together, they provide highly specialized cardiovascular care for patients ranging from babies in the womb to adults with congenital heart disease.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”